1252003-15-8

Basic information

• Product Name: Tubastatin-A
• Synonyms: N-Hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide;N-hydroxy-4-((2-methyl-2,3,4,5-tetrahydro-1H-indeno[1,2-c]pyridin-5-yl)methyl)benzamide;N-Hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide Tubastatin A;Tubastatin A BASE;Tubastatin A(free base);N-hydroxy-4-((2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)methyl)benzamide;N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)benzamide
• CAS NO: 1252003-15-8
• Molecular Formula: C₂₀H₂₁N₃O₂
• Molecular Weight: 335.39964
• Product Categories: Inhibitors
• Mol File: 1252003-15-8.mol

Chemical Properties

• Appearance: /
• Density: 1.28±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility: insoluble in EtOH; insoluble in H2O; ≥10.75 mg/mL in DMSO
• PKA: 8.95±0.10(Predicted)
• CAS DataBase Reference: Tubastatin-A(CAS DataBase Reference)
• NIST Chemistry Reference: Tubastatin-A(1252003-15-8)
• EPA Substance Registry System: Tubastatin-A(1252003-15-8)

Safety Data

• Hazardous Substances Data: 1252003-15-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tubastatin-A is used as a histone deacetylase 6 (HDAC6) inhibitor for its potential therapeutic applications in various diseases. Its high selectivity for HDAC6 makes it a promising candidate for the development of targeted therapies, particularly in the treatment of cancer. By inhibiting HDAC6, Tubastatin-A can modulate gene expression and cellular processes, leading to the regulation of cell growth, differentiation, and apoptosis.
Used in Cancer Research:
In the field of cancer research, Tubastatin-A is used as a tool to study the role of HDAC6 in tumorigenesis and cancer progression. Its ability to selectively inhibit HDAC6 allows researchers to investigate the molecular mechanisms underlying the development and progression of various types of cancer. This knowledge can be used to identify novel therapeutic targets and develop more effective cancer treatments.
Used in Drug Development:
Tubastatin-A is used as a lead compound in the development of new drugs targeting HDAC6. Its unique chemical structure and high selectivity for HDAC6 make it an attractive starting point for the design and synthesis of new HDAC6 inhibitors. These new compounds can potentially exhibit improved potency, selectivity, and pharmacokinetic properties, leading to more effective treatments for various diseases, including cancer.
Used in Drug Delivery Systems:
Similar to gallotannin, Tubastatin-A can also benefit from novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles can be employed as carriers for Tubastatin-A delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes. This approach can help overcome potential limitations associated with the drug's solubility, stability, and distribution within the body, ultimately leading to more effective treatments for patients.

Upstream product

• 1239034-70-8 4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)benzoic acid methyl ester 
• 100-63-0 phenylhydrazine 
• 1445-73-4 1-Methyl-4-piperidone 

Downstream Products

• 1239262-52-2 N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)benzamide trifluoroacetic acid salt 

Relevant articles and documents

HDAC6 inhibitor accelerates wound healing by inhibiting tubulin mediated IL-1β secretion in diabetic mice

Delayed wound healing in diabetes is characterized by sustained activation of inflammasome and increased expression of IL-1β in macrophages. Identification and validation of novel pathways to regulate IL-1β expression will provide therapeutic targets for

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

Structure-based drug design combined with homology modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isozyme compared to other inhibitors. These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies. An optimized compound from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity. Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress. Importantly, when given alone at all concentrations tested, this hydroxamate-containing HDAC6-selective compound displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogues to neurodegenerative conditions.